functional dyspepsia
Conditions
Interventions
group A:flupentixol and melitracen + nizatidine
group B:flupentixol and melitracen + rabeprazole
group C:flupentixol and melitracen
group D:nizatidine
group E:rabeprazole
Sponsors
The Third Xiangya Hospital, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 73 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years, the gender was male or female; 2. Meet the diagnostic criteria for functional dyspepsia; 3. The patients clearly understand and voluntarily participate in the study and sign informed consent.
Exclusion criteria
Exclusion criteria: Subjects who meet any of the following criteria will not be included in this study: 1. The patient's physical condition does not meet the medication requirements: (1) Previous history of gastric ulcer or abdominal surgery; (2) Malignant tumors associated with gastrointestinal tract or other sites; (3) Have taken antacid secretory drugs or psychotropic drugs within a week; (4) Women who were pregnant or lactating; (5) Allergic to flupentixol, melitoxin, rabeprazole or other proton pump inhibitors, nizatidine or other H2 receptor antagonists, Schizonus oryzae trypsin tablets, bifidobacterium capsules and other drugs; (6) There are alcohol, hypnotic drugs, psychotropic drugs, antidepressants and lithium drug acute poisoning; (7) Patients with adrenal pheochromocytoma; (8) Patients with acute angle-closure glaucoma; (9) Early recovery of myocardial infarction, various heart blocks or arrhythmias; (10) Taking monoamine oxidase inhibitors at the same time or stopping within 2 weeks (moclobeamide, selegiline); (11) Patients with organic brain injury, convulsions or Parkinson's disease; (12) Hyperthyroidism; (13) Myasthenia gravis; (14) Patients with hereditary galactose or fructose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption, or sucrase - isomaltase deficiency; (15) Patients with lower limb venous embolism; (16) Patients taking Azanavir sulfate. 2. Patients who do not agree to participate in this study 3. Other problems that do not meet the requirements of this study or affect the research results: (1) Suspected abuse of anti-anxiety and depression drugs, antacid secreting drugs, digestive enzymes drugs and other drugs; (2) Severe craniocerebral injury, severe mental illness, inability to communicate or other diseases that may affect follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gastrointestinal symptom scores, anxiety and depression scores; | — |
Countries
China
Contacts
Public ContactWang Fen
The Third Xiangya Hospital, Central South University
Outcome results
None listed